Grace Therapeutics (GRCE) Expected to Post Earnings on Tuesday

Grace Therapeutics (NASDAQ:GRCE) will likely be releasing its Q1 2027 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.1293) per share and revenue of $0.40 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2027 earning report for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:00 PM ET.

Grace Therapeutics (NASDAQ:GRCE) last issued its quarterly earnings results on Thursday, June 18th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.17.

Grace Therapeutics Price Performance

NASDAQ:GRCE traded up $0.01 on Tuesday, hitting $2.09. 54,616 shares of the company’s stock were exchanged, compared to its average volume of 447,524. The firm has a 50-day moving average price of $2.35 and a 200-day moving average price of $3.17. Grace Therapeutics has a 52 week low of $1.79 and a 52 week high of $5.18. The company has a market cap of $34.00 million, a P/E ratio of -4.35 and a beta of 0.39.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Grace Therapeutics in a research note on Friday, July 17th. Craig Hallum set a $4.00 target price on shares of Grace Therapeutics in a research note on Friday, April 24th. TD Cowen dropped their price target on shares of Grace Therapeutics from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, April 24th. Finally, Wall Street Zen cut shares of Grace Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $6.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. SeaCrest Wealth Management LLC bought a new stake in Grace Therapeutics in the 3rd quarter valued at $42,000. XTX Topco Ltd bought a new position in Grace Therapeutics during the fourth quarter worth $106,000. Renaissance Technologies LLC boosted its position in Grace Therapeutics by 53.5% during the fourth quarter. Renaissance Technologies LLC now owns 129,781 shares of the company’s stock worth $449,000 after purchasing an additional 45,220 shares during the period. ADAR1 Capital Management LLC increased its holdings in shares of Grace Therapeutics by 98.4% in the third quarter. ADAR1 Capital Management LLC now owns 350,450 shares of the company’s stock valued at $1,043,000 after purchasing an additional 173,823 shares during the last quarter. Finally, Cerity Partners LLC acquired a new position in shares of Grace Therapeutics in the fourth quarter valued at $1,463,000. 6.08% of the stock is currently owned by institutional investors.

Grace Therapeutics Company Profile

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.